 Emily Su
Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta | 20 | 2025 | 764 | 5.230 |
Why?
| | Fetal Growth Retardation | 14 | 2025 | 582 | 5.060 |
Why?
| | Endothelial Cells | 10 | 2023 | 816 | 2.430 |
Why?
| | Estrogen Receptor beta | 6 | 2012 | 43 | 1.800 |
Why?
| | Umbilical Arteries | 3 | 2024 | 54 | 1.700 |
Why?
| | Neovascularization, Physiologic | 4 | 2021 | 179 | 1.580 |
Why?
| | Pregnancy | 35 | 2025 | 7035 | 1.370 |
Why?
| | Extracellular Matrix | 2 | 2025 | 554 | 1.200 |
Why?
| | Hypertension | 10 | 2025 | 1250 | 1.140 |
Why?
| | Premature Birth | 6 | 2024 | 363 | 1.120 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2024 | 69 | 1.110 |
Why?
| | Pregnancy Complications, Cardiovascular | 8 | 2025 | 83 | 1.090 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 2 | 2019 | 18 | 1.060 |
Why?
| | Antihypertensive Agents | 8 | 2025 | 508 | 1.030 |
Why?
| | Endometriosis | 6 | 2012 | 57 | 0.970 |
Why?
| | Chorionic Villi | 2 | 2024 | 25 | 0.870 |
Why?
| | Integrin alphaVbeta3 | 1 | 2022 | 18 | 0.770 |
Why?
| | Cell Movement | 4 | 2021 | 962 | 0.730 |
Why?
| | Proteome | 2 | 2025 | 483 | 0.720 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 71 | 0.700 |
Why?
| | Otoacoustic Emissions, Spontaneous | 1 | 2020 | 5 | 0.680 |
Why?
| | Acoustic Impedance Tests | 1 | 2020 | 13 | 0.680 |
Why?
| | Prostaglandins | 2 | 2011 | 97 | 0.640 |
Why?
| | Neovascularization, Pathologic | 2 | 2019 | 295 | 0.640 |
Why?
| | Artificial Intelligence | 1 | 2024 | 342 | 0.620 |
Why?
| | Pre-Eclampsia | 6 | 2024 | 200 | 0.610 |
Why?
| | Proteomics | 2 | 2025 | 1137 | 0.610 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 2019 | 8 | 0.600 |
Why?
| | Progesterone | 4 | 2010 | 258 | 0.600 |
Why?
| | Fetus | 5 | 2023 | 797 | 0.600 |
Why?
| | 17-Hydroxysteroid Dehydrogenases | 2 | 2010 | 5 | 0.590 |
Why?
| | Estrogens | 2 | 2012 | 371 | 0.590 |
Why?
| | Panuveitis | 1 | 2019 | 8 | 0.590 |
Why?
| | Adalimumab | 1 | 2019 | 55 | 0.580 |
Why?
| | Female | 48 | 2025 | 75814 | 0.580 |
Why?
| | Pregnancy Outcome | 7 | 2024 | 453 | 0.510 |
Why?
| | Benzo(a)pyrene | 1 | 2016 | 8 | 0.500 |
Why?
| | Cyclooxygenase 2 | 3 | 2016 | 172 | 0.490 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2022 | 547 | 0.480 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2016 | 57 | 0.480 |
Why?
| | Endothelium, Vascular | 5 | 2018 | 943 | 0.480 |
Why?
| | Signal Transduction | 5 | 2019 | 5116 | 0.440 |
Why?
| | Humans | 51 | 2025 | 141284 | 0.440 |
Why?
| | Endometrium | 4 | 2012 | 62 | 0.420 |
Why?
| | Stromal Cells | 4 | 2025 | 117 | 0.410 |
Why?
| | Fibronectins | 2 | 2025 | 135 | 0.410 |
Why?
| | Reproduction | 2 | 2012 | 206 | 0.400 |
Why?
| | Umbilical Cord | 1 | 2013 | 87 | 0.380 |
Why?
| | Cell Proliferation | 2 | 2018 | 2502 | 0.380 |
Why?
| | Stillbirth | 1 | 2013 | 74 | 0.380 |
Why?
| | Fetal Diseases | 1 | 2013 | 180 | 0.350 |
Why?
| | Birth Weight | 4 | 2025 | 511 | 0.340 |
Why?
| | Infant, Newborn | 13 | 2025 | 6270 | 0.340 |
Why?
| | Endothelium | 1 | 2011 | 119 | 0.340 |
Why?
| | Ultrasonography, Doppler | 2 | 2024 | 122 | 0.310 |
Why?
| | Women's Health | 1 | 2012 | 308 | 0.310 |
Why?
| | Adult | 19 | 2025 | 39319 | 0.300 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 269 | 0.300 |
Why?
| | Estradiol | 3 | 2011 | 523 | 0.290 |
Why?
| | Promegestone | 1 | 2007 | 33 | 0.270 |
Why?
| | Infant, Small for Gestational Age | 2 | 2025 | 103 | 0.270 |
Why?
| | Postpartum Period | 3 | 2024 | 345 | 0.260 |
Why?
| | Up-Regulation | 3 | 2019 | 851 | 0.240 |
Why?
| | Estrogen Receptor alpha | 3 | 2012 | 145 | 0.240 |
Why?
| | Fetal Development | 2 | 2023 | 296 | 0.230 |
Why?
| | Dystonia | 1 | 2025 | 28 | 0.230 |
Why?
| | Pregnancy Trimester, Third | 1 | 2025 | 113 | 0.220 |
Why?
| | Chronic Disease | 7 | 2025 | 1807 | 0.220 |
Why?
| | Placental Circulation | 2 | 2017 | 71 | 0.220 |
Why?
| | Labetalol | 1 | 2024 | 6 | 0.220 |
Why?
| | Nifedipine | 1 | 2024 | 29 | 0.220 |
Why?
| | Case-Control Studies | 4 | 2021 | 3577 | 0.210 |
Why?
| | Hip Fractures | 1 | 2025 | 85 | 0.210 |
Why?
| | Hypotension | 1 | 2025 | 126 | 0.210 |
Why?
| | Uterus | 2 | 2017 | 221 | 0.200 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 162 | 0.200 |
Why?
| | Running | 1 | 2025 | 229 | 0.200 |
Why?
| | Integrin alpha5beta1 | 1 | 2022 | 9 | 0.190 |
Why?
| | Gestational Age | 5 | 2024 | 952 | 0.190 |
Why?
| | Cost of Illness | 1 | 2025 | 311 | 0.190 |
Why?
| | Breast Feeding | 2 | 2024 | 441 | 0.190 |
Why?
| | Regional Blood Flow | 2 | 2017 | 497 | 0.190 |
Why?
| | Cannabidiol | 1 | 2024 | 126 | 0.190 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 124 | 0.190 |
Why?
| | Cells, Cultured | 5 | 2021 | 4149 | 0.190 |
Why?
| | Epoprostenol | 2 | 2016 | 131 | 0.190 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 156 | 0.190 |
Why?
| | Dronabinol | 1 | 2024 | 240 | 0.180 |
Why?
| | Furin | 1 | 2021 | 14 | 0.170 |
Why?
| | Trophoblasts | 2 | 2021 | 210 | 0.170 |
Why?
| | Otoscopy | 1 | 2020 | 8 | 0.170 |
Why?
| | Reperfusion Injury | 1 | 2023 | 291 | 0.170 |
Why?
| | Drug Monitoring | 1 | 2024 | 396 | 0.170 |
Why?
| | New Zealand | 1 | 2020 | 55 | 0.170 |
Why?
| | Steroidogenic Factor 1 | 2 | 2012 | 12 | 0.170 |
Why?
| | Receptors, Virus | 1 | 2021 | 95 | 0.170 |
Why?
| | Serine Endopeptidases | 1 | 2021 | 124 | 0.160 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 91 | 0.160 |
Why?
| | Receptors, Progesterone | 3 | 2012 | 337 | 0.160 |
Why?
| | Fibroblasts | 1 | 2025 | 1018 | 0.160 |
Why?
| | Cohort Studies | 4 | 2024 | 5809 | 0.160 |
Why?
| | RNA Interference | 3 | 2011 | 465 | 0.150 |
Why?
| | Models, Biological | 2 | 2017 | 1810 | 0.150 |
Why?
| | Triamcinolone | 1 | 2019 | 13 | 0.150 |
Why?
| | Parkinson Disease | 1 | 2025 | 571 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 83 | 0.140 |
Why?
| | Hospitalization | 2 | 2025 | 2264 | 0.140 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1939 | 0.140 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 118 | 0.140 |
Why?
| | Remission Induction | 1 | 2019 | 306 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 656 | 0.140 |
Why?
| | Headache | 1 | 2019 | 153 | 0.140 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 175 | 0.140 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2600 | 0.130 |
Why?
| | Blood Pressure | 4 | 2025 | 1740 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 983 | 0.130 |
Why?
| | Fetal Blood | 2 | 2017 | 335 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1105 | 0.130 |
Why?
| | Systems Biology | 1 | 2017 | 70 | 0.130 |
Why?
| | Pluripotent Stem Cells | 1 | 2017 | 80 | 0.130 |
Why?
| | Morphogenesis | 1 | 2017 | 169 | 0.130 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 258 | 0.130 |
Why?
| | Mental Disorders | 1 | 2025 | 1133 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2020 | 1037 | 0.120 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 49 | 0.120 |
Why?
| | Organoids | 1 | 2017 | 128 | 0.120 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1100 | 0.120 |
Why?
| | Epigenesis, Genetic | 2 | 2012 | 661 | 0.120 |
Why?
| | Visual Acuity | 1 | 2019 | 449 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 822 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1043 | 0.120 |
Why?
| | Cilia | 1 | 2017 | 170 | 0.120 |
Why?
| | Cesarean Section | 3 | 2024 | 213 | 0.120 |
Why?
| | Maternal-Fetal Exchange | 1 | 2016 | 170 | 0.110 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 411 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2019 | 1220 | 0.100 |
Why?
| | Cell Cycle | 1 | 2017 | 601 | 0.100 |
Why?
| | Abruptio Placentae | 2 | 2024 | 6 | 0.100 |
Why?
| | Vascular Resistance | 1 | 2015 | 364 | 0.100 |
Why?
| | Growth Disorders | 1 | 2014 | 87 | 0.100 |
Why?
| | Infant, Premature | 2 | 2017 | 599 | 0.100 |
Why?
| | Fetal Distress | 1 | 2012 | 14 | 0.090 |
Why?
| | Ovarian Diseases | 1 | 2012 | 13 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2010 | 1439 | 0.090 |
Why?
| | Oogenesis | 1 | 2012 | 19 | 0.090 |
Why?
| | Ovulation | 1 | 2012 | 40 | 0.090 |
Why?
| | Placentation | 1 | 2012 | 46 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 45 | 0.090 |
Why?
| | Eicosanoids | 1 | 2012 | 59 | 0.090 |
Why?
| | Pregnancy Proteins | 1 | 2012 | 35 | 0.090 |
Why?
| | Chorioamnionitis | 1 | 2012 | 45 | 0.090 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2017 | 402 | 0.090 |
Why?
| | Muscle Tonus | 1 | 2011 | 23 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2025 | 16447 | 0.090 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2011 | 73 | 0.090 |
Why?
| | Parturition | 1 | 2012 | 67 | 0.090 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 183 | 0.080 |
Why?
| | Ultrasonography | 1 | 2015 | 765 | 0.080 |
Why?
| | Animals | 7 | 2023 | 37328 | 0.080 |
Why?
| | Large Neutral Amino Acid-Transporter 1 | 1 | 2010 | 15 | 0.080 |
Why?
| | Myometrium | 1 | 2010 | 39 | 0.080 |
Why?
| | Vasoconstriction | 1 | 2011 | 215 | 0.080 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 24 | 0.080 |
Why?
| | Leiomyoma | 1 | 2010 | 56 | 0.080 |
Why?
| | Prospective Studies | 4 | 2024 | 7805 | 0.080 |
Why?
| | Child, Preschool | 2 | 2024 | 11511 | 0.080 |
Why?
| | Apoptosis | 1 | 2018 | 2487 | 0.080 |
Why?
| | Uterine Neoplasms | 1 | 2010 | 93 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2010 | 66 | 0.080 |
Why?
| | Thromboxanes | 1 | 2009 | 14 | 0.080 |
Why?
| | Blotting, Western | 1 | 2011 | 1220 | 0.070 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 420 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 435 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 258 | 0.070 |
Why?
| | Vasodilation | 1 | 2011 | 512 | 0.070 |
Why?
| | Glucocorticoids | 1 | 2012 | 534 | 0.070 |
Why?
| | Retinoid X Receptor alpha | 1 | 2007 | 3 | 0.070 |
Why?
| | Progesterone Congeners | 1 | 2007 | 15 | 0.070 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2007 | 16 | 0.070 |
Why?
| | Receptors, Retinoic Acid | 1 | 2007 | 41 | 0.070 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2246 | 0.070 |
Why?
| | Aromatase | 1 | 2007 | 31 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2017 | 1983 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1724 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1244 | 0.060 |
Why?
| | Immunoblotting | 1 | 2007 | 308 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 381 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1449 | 0.060 |
Why?
| | Endometrial Neoplasms | 1 | 2007 | 196 | 0.060 |
Why?
| | Arterial Pressure | 1 | 2024 | 132 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2010 | 2815 | 0.050 |
Why?
| | Kidney Tubules, Proximal | 1 | 2023 | 128 | 0.050 |
Why?
| | Mice | 3 | 2023 | 17969 | 0.050 |
Why?
| | Kidney | 2 | 2023 | 1482 | 0.050 |
Why?
| | Male | 6 | 2025 | 70140 | 0.050 |
Why?
| | Biomarkers | 3 | 2022 | 4180 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 79 | 0.050 |
Why?
| | Triage | 1 | 2024 | 250 | 0.050 |
Why?
| | Administration, Oral | 1 | 2024 | 825 | 0.040 |
Why?
| | Fetal Hypoxia | 1 | 2022 | 55 | 0.040 |
Why?
| | Middle Aged | 4 | 2025 | 34658 | 0.040 |
Why?
| | Virus Internalization | 1 | 2021 | 64 | 0.040 |
Why?
| | Ovarian Neoplasms | 1 | 2007 | 581 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 496 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1265 | 0.040 |
Why?
| | Child | 1 | 2019 | 22390 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2795 | 0.040 |
Why?
| | Synthetic Biology | 1 | 2017 | 13 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 874 | 0.030 |
Why?
| | Altitude | 1 | 2022 | 475 | 0.030 |
Why?
| | Transcriptome | 1 | 2023 | 1007 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 26 | 0.030 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 1 | 2017 | 32 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 89 | 0.030 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2017 | 55 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2017 | 148 | 0.030 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2021 | 408 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2069 | 0.030 |
Why?
| | Microvilli | 1 | 2016 | 75 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 84 | 0.030 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 67 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2390 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 391 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 306 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2016 | 244 | 0.030 |
Why?
| | Aged | 2 | 2025 | 24836 | 0.030 |
Why?
| | United States | 2 | 2025 | 15298 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 309 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 324 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 528 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2017 | 341 | 0.030 |
Why?
| | Actins | 1 | 2017 | 426 | 0.030 |
Why?
| | Adolescent | 1 | 2013 | 22116 | 0.030 |
Why?
| | Tissue Engineering | 1 | 2017 | 429 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 6951 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2023 | 4414 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2025 | 7948 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2210 | 0.020 |
Why?
| | Cardiotocography | 1 | 2012 | 5 | 0.020 |
Why?
| | Young Adult | 2 | 2024 | 13727 | 0.020 |
Why?
| | Fetal Monitoring | 1 | 2012 | 20 | 0.020 |
Why?
| | Heart Rate, Fetal | 1 | 2012 | 24 | 0.020 |
Why?
| | Genomics | 1 | 2017 | 811 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 117 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2863 | 0.020 |
Why?
| | Mifepristone | 1 | 2010 | 63 | 0.020 |
Why?
| | Hormone Antagonists | 1 | 2010 | 34 | 0.020 |
Why?
| | Infant | 1 | 2024 | 9820 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11216 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 164 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1005 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2929 | 0.020 |
Why?
| | Dinoprostone | 1 | 2008 | 179 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1123 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2047 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1761 | 0.010 |
Why?
| | DNA Methylation | 1 | 2010 | 643 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2904 | 0.010 |
Why?
| | Transcription Factors | 1 | 2008 | 1706 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2840 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|